---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-267185"
form_type: "8-K"
ticker: "ABOS"
cik: "0001576885"
company_name: "Acumen Pharmaceuticals, Inc."
filed_at: "2022-10-24T23:59:59+00:00"
generated_at: "2026-06-23T01:38:42.104203+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Acumen's ACU193 receives FDA Fast Track designation for early Alzheimer's disease

## Summary
- ACU193 is first clinical-stage monoclonal antibody selectively targeting toxic soluble amyloid beta oligomers (AßOs).
- Phase 1 INTERCEPT-AD trial ongoing to assess safety and proof of mechanism.
- Fast Track facilitates more frequent FDA engagement to expedite development and review.
- ACU193's unique binding profile may offer low risk of ARIA by avoiding direct plaque targeting.
- CEO Daniel O'Connell cites potential clinical utility and collaboration with FDA.

## SEC filing metadata
- accession: 0001193125-22-267185
- form_type: 8-K
- ticker: ABOS
- cik: 0001576885
- company_name: Acumen Pharmaceuticals, Inc.
- filed_at: 2022-10-24T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576885/000119312522267185/0001193125-22-267185-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576885/000119312522267185/d358925d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-267185
- JSON: https://secwatch.observer/filing/0001193125-22-267185.json
- Plain text: https://secwatch.observer/filing/0001193125-22-267185.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.